INTENSITY THERAPEUTICS, INC. Retained Earnings
INTENSITY THERAPEUTICS, INC. (INTS) had Retained Earnings of -$83.83 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$83.83M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$80.82M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$78.39M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$75.34M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$83.83M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | -$80.82M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | -$78.39M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | -$75.34M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$72.67M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | -$70.13M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | -$66.78M 10-K · filed 2026-03-27 | |
| 2024-09-30 | -$63.60M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | -$60.09M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$55.12M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | -$50.52M 10-K · filed 2025-03-13 | |
| 2023-09-30 | -$47.34M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | -$43.69M 10-Q · filed 2023-08-14 | |
| 2022-12-31 | -$38.65M 10-K · filed 2024-03-14 | -$38.65M 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |